This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction: New Trends in Treating Premenstrual Dysphoric Disorder

Lee S. Cohen, MD

Published: October 30, 2000

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Premenstural dysphoric disorder (PMDD) affects 3% to 8% of women with regular menstrual cycles. Symptoms of PMDD include a range of emotional and somatic symptoms that are limited to the luteal phase of the menstrual cycle (the last 14 days prior to menses) and that interfere with occupational and social functioning. Clinicians who care for women must differentiate PMDD from a spectrum of other conditions that may present with similar symptoms. PMDD is a discrete diagnostic entity with attendant suffering and impairment of functioning.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 2

Quick Links: Psychiatry


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...